{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bluett B"],"funding":["NICHD NIH HHS","NIA NIH HHS","NINDS NIH HHS"],"pagination":["694872"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8284317"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12"],"pubmed_abstract":["Progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS; the most common phenotype of corticobasal degeneration) are tauopathies with a relentless course, usually starting in the mid-60s and leading to death after an average of 7 years. There is as yet no specific or disease-modifying treatment. Clinical deficits in PSP are numerous, involve the entire neuraxis, and present as several discrete phenotypes. They center on rigidity, bradykinesia, postural instability, gait freezing, supranuclear ocular motor impairment, dysarthria, dysphagia, incontinence, sleep disorders, frontal cognitive dysfunction, and a variety of behavioral changes. CBS presents with prominent and usually asymmetric dystonia, apraxia, myoclonus, pyramidal signs, and cortical sensory loss. The symptoms and d"],"journal":["Frontiers in neurology"],"pubmed_title":["Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care."],"pmcid":["PMC8284317"],"funding_grant_id":["U01 NS102035","P01 AG066597","K23 AG059891","P2C HD086844"],"pubmed_authors":["Bower J","Dhall R","Bluett B","Fleisher JE","Plummer LS","Sidiropoulos C","Ljubenkov PA","Duquette A","Pantelyat AY","Patel P","Litvan I","Howell M","Boxer AL","Wilhelm J","Myrick E","Lepage C","Xie T","Ali F","Leegwater-Kim J","Rojas J","VandeVrede L","Dale ML","Sokol LL","Grossman M","McFarland NR","Golbe LI","Moretti P","Mancini M","Sklerov M","Apetauerova D","Tuite PJ","Bloom L","Rodriguez-Porcel F","Wills AA","Fernandez HH","Bega D","Kerwin DR"],"additional_accession":[]},"is_claimable":false,"name":"Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care.","description":"Progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS; the most common phenotype of corticobasal degeneration) are tauopathies with a relentless course, usually starting in the mid-60s and leading to death after an average of 7 years. There is as yet no specific or disease-modifying treatment. Clinical deficits in PSP are numerous, involve the entire neuraxis, and present as several discrete phenotypes. They center on rigidity, bradykinesia, postural instability, gait freezing, supranuclear ocular motor impairment, dysarthria, dysphagia, incontinence, sleep disorders, frontal cognitive dysfunction, and a variety of behavioral changes. CBS presents with prominent and usually asymmetric dystonia, apraxia, myoclonus, pyramidal signs, and cortical sensory loss. The symptoms and d","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2025-05-29T19:01:38.145Z","creation":"2025-05-29T19:01:38.145Z"},"accession":"S-EPMC8284317","cross_references":{"pubmed":["34276544"],"doi":["10.3389/fneur.2021.694872"]}}